Loading stock data…
$5.38-0.12 (-2.18%)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Alvotech in the Healthcare sector is trading at $5.38 with a market capitalization of $1.9B. Wall Street consensus targets $6.80 (5 analysts), implying a +26.4% move over the next 12 months. The stock is currently 41% below its 52-week high of $9.04, remaining 27.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $105.77M | $105.86M↓ | $166.57M↑ | $113.74M↓ | $173.24M |
| Gross Profit | $53.58M↓ | $59.78M↓ | $105.29M↑ | $78.74M↓ | $99.41M |
| Operating Income | -$11.71M↓ | $9.67M↓ | $48.26M↑ | $1.31M↓ | $18.06M |
| Net Income | -$66.82M↓ | $1.03M↑ | -$108.55M↓ | -$5.25M↓ | $32.04M |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a...